


Patent Application  
Attorney Docket No. PC11805A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 30th day of September 2003.

By

  
(Signature of person mailing)  
Kelley D. Surprenant

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Laura C. Blumberg, et al. :

APPLICATION NO.: 10/616,843 : Examiner: To be assigned

FILING DATE: July 8, 2003 : Group Art Unit: To be assigned

TITLE: Novel Piperadine Derivatives :

Hon. Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.


The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

This Information Disclosure Statement is being mailed before receiving the first action on the merits. Therefore, no fee is believed to be due. However, the Commissioner is authorized to charge any fee that may be required to Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Date: September 30, 2003

Respectfully submitted,



Lisa A. Samuels  
Attorney for Applicant(s)  
Reg. No. 43,080

Pfizer Inc.  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 686-0349



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO. PC11805A	SERIAL NO. 10/616,843
	APPLICANT Laura C. Blumberg, et al.	
	FILING DATE July 8, 2003	GROUP To be assigned

U.S. PATENT DOCUMENTS													
EXAMINER INITIAL	DOCUMENT NUMBER								DATE	NAME	CLAS S	SUBCLA SS	FILING DATE IF APPROPRIATE
	US	3	5	3	8	2	1	4	11/3/70	Polli, G. P., et al	424	19	
	US	4	0	6	0	5	9	8	11/29/77	Groppenbacher, G., et al.	424	33	
	US	3	1	1	9	7	4	2	1/28/64	Heimlich, K., et al.	167	82	
	US	3	4	9	2	3	9	7	1/27/70	Peters, D., et al.	424	20	

FOREIGN PATENT DOCUMENTS													
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
													YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)													
			Teran, L. M., et al., <i>Eosinophil Recruitment Following Allergen Challenge is Associated with the Release of the Chemokine RANTES into Asthmatic Airways</i> , The Journal of Immunology, pp. 1806-1812, (1996).										
			Combadiere, C., et al., <i>Monocyte Chemoattractant Protein-3 is a Functional Ligand for CC Chemokine Receptors 1 and 2B</i> , The Journal of Biological Chemistry, vol. 270, no. 50, pp. 29671-29675, (1995).										
			Smith, R. E., et al., <i>Production and Function of Murine Macrophage Inflammatory Protein-1<math>\alpha</math> in Bleomycin-Induced Lung Injury</i> , The Journal of Immunology, pp. 4704-4712, (1994).										
			Cook, D. N., et al., <i>Requirement of MIP-1<math>\alpha</math> for an Inflammatory Response to Viral Infection</i> , Science, vol. 269, pp. 1583-1585, (15 September 1995).										
			Kuna, P., et al., <i>Studies of MCAF/MCP-1, Rantes, MTP-1 <math>\alpha</math>, IL-9, Histamine, ECP and Tryptase in Allergic Rhinitis Sufferers and Asymptomatic Subjects</i> , J. Allergy Clin. Immunol., no. 321, page 215, (1994).										
			Coligan, J. E., et al., <i>Current Protocols in Immunology</i> , 6.12.1-6.12.3, (1991).										

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.